EXEM FOAM KIT Drug Patent Profile

Which patents cover Exem Foam Kit, and what generic alternatives are available?

Exem Foam Kit is a drug marketed by Giskit and is included in one NDA. There are three patents protecting this drug.

This drug has six patent family members in six countries.

The generic ingredient in EXEM FOAM KIT is air polymer-type a. There are thirty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the air polymer-type a profile page.

DrugPatentWatch^® Generic Entry Outlook for Exem Foam Kit

Exem Foam Kit was eligible for patent challenges on November 7, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 15, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for EXEM FOAM KIT

International Patents:	6
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	EXEM FOAM KIT at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EXEM FOAM KIT

NDA:

212279

Dosage:

FOAM;INTRAUTERINE

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for EXEM FOAM KIT

EXEM FOAM KIT is protected by three US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Giskit	EXEM FOAM KIT	air polymer-type a	FOAM;INTRAUTERINE	212279-001	Nov 7, 2019		RX	Yes	Yes			Y
Giskit	EXEM FOAM KIT	air polymer-type a	FOAM;INTRAUTERINE	212279-001	Nov 7, 2019		RX	Yes	Yes			Y
Giskit	EXEM FOAM KIT	air polymer-type a	FOAM;INTRAUTERINE	212279-001	Nov 7, 2019		RX	Yes	Yes			Y

International Patents for EXEM FOAM KIT

When does loss-of-exclusivity occur for EXEM FOAM KIT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Denmark

European Patent Office

Netherlands

Poland

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EXEM FOAM KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	2488211
Denmark	2488211
Spain	2529564
Netherlands	2003660
European Patent Office	2488211	Composition et procédé d'imagerie médicale de cavités corporelles (Composition and method for medical imaging of body cavities)
World Intellectual Property Organization (WIPO)	2011046437

EXEM FOAM KIT Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is EXEM FOAM KIT?

EXEM FOAM KIT is a prescription topical treatment approved for the treatment of moderate-to-severe atopic dermatitis (eczema) in individuals aged 12 years and older. The active pharmaceutical ingredient is pimecrolimus, a calcineurin inhibitor. The foam formulation is designed to improve adherence and ease of application compared to traditional cream or ointment formulations. The U.S. Food and Drug Administration (FDA) approved EXEM FOAM KIT in October 2022 [1].

What is the Market Landscape for Atopic Dermatitis Treatments?

The global market for atopic dermatitis treatments is substantial and growing. This growth is driven by increasing prevalence of the condition, rising awareness among patients and healthcare providers, and the development of novel therapeutic options. Key market segments include topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), topical phosphodiesterase-4 (PDE4) inhibitors, and the emerging class of biologic therapies.

In 2022, the global atopic dermatitis market was valued at approximately $12.9 billion and is projected to reach $25.7 billion by 2030, representing a compound annual growth rate (CAGR) of 9.0% [2].

Competitive Landscape

EXEM FOAM KIT enters a competitive market with established players and a pipeline of innovative therapies.

• Topical Corticosteroids (TCS): These remain first-line therapy for mild to moderate atopic dermatitis due to their efficacy and low cost. However, long-term use is associated with side effects such as skin thinning and striae. Examples include triamcinolone, betamethasone, and clobetasol [3].
• Topical Calcineurin Inhibitors (TCIs): EXEM FOAM KIT is a TCI. Other approved TCIs include tacrolimus (Protopic) and pimecrolimus cream (Elidel). These are often used for sensitive skin areas or when steroid-sparing options are desired. The foam formulation of pimecrolimus aims to improve patient experience and compliance.
• Topical PDE4 Inhibitors: Crisaborole (Eucrisa) is a topical PDE4 inhibitor approved for mild-to-moderate atopic dermatitis. It works by reducing inflammation.
• Systemic Therapies: For moderate-to-severe cases not controlled by topical therapies, systemic treatments are employed. These include oral corticosteroids, immunosuppressants (e.g., cyclosporine, methotrexate), and more recently, Janus kinase (JAK) inhibitors [3].
• Biologics: These are a significant growth area for moderate-to-severe atopic dermatitis. Dupilumab (Dupixent), an interleukin-4 receptor alpha antagonist, has demonstrated strong efficacy and safety. Other biologics targeting different inflammatory pathways are also in development and on the market, including tralokinumab (Adbry) and various JAK inhibitors such as upadacitinib (Rinvoq) and abrocitinib (Cibinqo) [4, 5].

The introduction of EXEM FOAM KIT, with its novel delivery system, is positioned to capture market share by addressing unmet needs related to application comfort and patient adherence, particularly for patients who may have had suboptimal experiences with existing topical formulations.

What are the Key Clinical and Regulatory Aspects of EXEM FOAM KIT?

EXEM FOAM KIT's approval was based on robust clinical trial data demonstrating its efficacy and safety profile.

Clinical Trial Data

The FDA approval was supported by two Phase 3 studies, P306 and P307, which evaluated the safety and efficacy of pimecrolimus foam for atopic dermatitis.

• Study Design: These were randomized, double-blind, vehicle-controlled, parallel-group studies [1].
• Patient Population: Included individuals aged 12 to 75 years with moderate-to-severe atopic dermatitis.
• Primary Endpoint: The primary endpoint was the proportion of subjects achieving treatment success, defined as a score of 0 or 1 on the Investigator's Global Assessment (IGA) scale, with at least a 2-grade improvement from baseline, at week 8 [1].
• Efficacy Results:
  • In P306, 35.2% of subjects treated with pimecrolimus foam achieved the primary endpoint compared to 17.4% treated with vehicle foam (p < 0.001) [1].
  • In P307, 39.7% of subjects treated with pimecrolimus foam achieved the primary endpoint compared to 20.4% treated with vehicle foam (p < 0.001) [1].
• Safety Profile: The most common adverse events reported in clinical trials were application site reactions, including stinging, burning, and itching. These were generally mild to moderate and transient [1]. The safety profile aligns with that of other pimecrolimus products.

Regulatory Status

• FDA Approval Date: October 11, 2022 [1].
• Indications: Treatment of moderate-to-severe atopic dermatitis in individuals aged 12 years and older.
• Dosage and Administration: Applied twice daily to affected areas.

The approval of EXEM FOAM KIT by the FDA signifies its demonstrated benefit and acceptable risk profile for its intended patient population.

What is the Projected Financial Trajectory and Market Potential for EXEM FOAM KIT?

The financial trajectory of EXEM FOAM KIT is dependent on its market penetration, pricing strategy, and the evolving competitive landscape.

Market Penetration Drivers

• Improved Patient Experience: The foam formulation is a key differentiator, potentially leading to higher patient satisfaction and adherence, which can translate to sustained prescription volume.
• Physician Adoption: Positive clinical data and a favorable safety profile are crucial for physician prescribing habits. The novel delivery system may encourage physicians to recommend it for patients who have struggled with traditional topicals.
• Reimbursement and Payer Coverage: Securing favorable formulary placement and reimbursement from major payers is critical for market access and patient affordability. This process typically takes time following approval.
• Marketing and Sales Efforts: Aggressive and effective marketing campaigns targeting dermatologists, allergists, and primary care physicians will be essential to drive awareness and prescriptions.

Pricing Strategy and Revenue Potential

The pricing of EXEM FOAM KIT will be a key determinant of its revenue potential. As a novel formulation of an existing active ingredient, its price will likely be positioned competitively within the TCI class, but potentially at a premium compared to generic pimecrolimus cream or older-generation TCS.

While specific revenue projections are proprietary, an analysis of comparable product launches and the overall market size for atopic dermatitis treatments suggests significant revenue potential. If EXEM FOAM KIT can capture even a modest share of the estimated $12.9 billion global market, its sales could reach hundreds of millions of dollars annually. Factors influencing this include:

• Number of Prescriptions: Driven by physician adoption and patient demand.
• Average Wholesale Price (AWP): The list price of the product.
• Net Price Realization: Actual revenue after discounts, rebates, and payer adjustments.
• Duration of Therapy: Atopic dermatitis is a chronic condition, suggesting potential for long-term treatment, assuming efficacy and tolerability.

Impact of Competition

The market for atopic dermatitis is dynamic. The increasing number of biologic and oral systemic therapies for moderate-to-severe disease could influence the treatment algorithm. However, topical therapies like EXEM FOAM KIT remain a cornerstone for many patients, especially those with milder disease or as maintenance therapy. The key will be to position EXEM FOAM KIT effectively within this algorithm, emphasizing its role as a well-tolerated and effective topical option with an improved patient experience.

What are the Risks and Challenges?

Despite its potential, EXEM FOAM KIT faces several risks and challenges:

• Market Saturation and Competition: The atopic dermatitis market is crowded with numerous treatment options. Differentiating EXEM FOAM KIT and demonstrating clear clinical and economic value to payers and prescribers will be critical.
• Payer Restrictions and Reimbursement Hurdles: Achieving broad formulary access and favorable reimbursement terms from insurance providers is essential. Stricter prior authorization requirements or step-therapy protocols could limit uptake.
• Physician and Patient Education: Educating healthcare providers and patients about the benefits and proper use of the foam formulation will require significant marketing and medical affairs investment.
• Adverse Event Profile: While the safety profile is generally favorable, any unexpected safety signals that emerge post-launch could negatively impact adoption.
• Manufacturing and Supply Chain: Ensuring consistent and high-quality manufacturing and a reliable supply chain is paramount for sustained market presence.

Key Takeaways

EXEM FOAM KIT represents a novel formulation of pimecrolimus, a proven calcineurin inhibitor, for the treatment of moderate-to-severe atopic dermatitis. Its foam delivery system offers potential advantages in patient adherence and experience. The drug enters a large and growing market segment with significant unmet needs. Clinical trials demonstrate its efficacy and safety, supporting its FDA approval. The financial trajectory will be shaped by its ability to gain market share against established topical and emerging systemic/biologic therapies, effective marketing, favorable payer coverage, and successful physician adoption. Risks include intense competition, reimbursement challenges, and the need for robust patient and physician education.

Frequently Asked Questions

What is the key difference between EXEM FOAM KIT and existing pimecrolimus products?

The primary difference is the formulation. EXEM FOAM KIT is a foam, designed for easier application and potentially better tolerability and adherence compared to traditional creams or ointments.

What is the target patient population for EXEM FOAM KIT?

EXEM FOAM KIT is indicated for individuals aged 12 years and older with moderate-to-severe atopic dermatitis.

How does EXEM FOAM KIT work to treat atopic dermatitis?

EXEM FOAM KIT contains pimecrolimus, a calcineurin inhibitor. It works by suppressing the immune system's inflammatory response in the skin, which is a key factor in atopic dermatitis.

What are the most common side effects associated with EXEM FOAM KIT?

The most frequently reported adverse events in clinical trials were application site reactions, such as stinging, burning, and itching. These were typically mild to moderate and temporary.

How is EXEM FOAM KIT expected to perform financially in the current atopic dermatitis market?

The financial success of EXEM FOAM KIT will depend on its ability to secure broad payer coverage, achieve significant physician prescription volume, and effectively differentiate its novel foam formulation against a competitive landscape that includes established topical treatments and newer biologic and systemic therapies.

---

Citations

[1] U.S. Food & Drug Administration. (2022, October 11). FDA approves EXEM FOAM KIT (pimecrolimus) foam for the treatment of moderate-to-severe atopic dermatitis. [Press release]. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fday-approves-exem-foam-kit-pimecrolimus-foam-treatment-moderate-severe-atopic-dermatitis

[2] Grand View Research. (2023). Atopic Dermatitis Market Size, Share & Trends Analysis Report By Treatment (Drug Class, Therapy Type), By Indication (Mild, Moderate, Severe), By End-use (Hospitals, Clinics, Homecare), By Region, And Segment Forecasts, 2023 – 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/atopic-dermatitis-market

[3] National Eczema Association. (n.d.). Treatments. Retrieved from https://eczema.org/treatment/

[4] Regeneron Pharmaceuticals, Inc. & Sanofi. (2023). Dupixent (dupilumab) prescribing information. Retrieved from https://www.regeneron.com/dupixent (Note: Specific prescribing information URL may change; direct to company website for current details).

[5] AbbVie Inc. (2023). Rinvoq (upadacitinib) prescribing information. Retrieved from https://www.rxabbvie.com/products/rinvoq (Note: Specific prescribing information URL may change; direct to company website for current details).